ES2784900T3 - Tratamiento de metástasis cerebrales del cáncer de mama - Google Patents

Tratamiento de metástasis cerebrales del cáncer de mama Download PDF

Info

Publication number
ES2784900T3
ES2784900T3 ES15816534T ES15816534T ES2784900T3 ES 2784900 T3 ES2784900 T3 ES 2784900T3 ES 15816534 T ES15816534 T ES 15816534T ES 15816534 T ES15816534 T ES 15816534T ES 2784900 T3 ES2784900 T3 ES 2784900T3
Authority
ES
Spain
Prior art keywords
substituted
seq
unsubstituted
her3
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15816534T
Other languages
English (en)
Spanish (es)
Inventor
Qing Sheng
Rakesh K Jain
Vasileios Askoxylakis
Gino B Ferraro
Dai Fukumura
David P Kodack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
General Hospital Corp
Original Assignee
Novartis AG
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, General Hospital Corp filed Critical Novartis AG
Application granted granted Critical
Publication of ES2784900T3 publication Critical patent/ES2784900T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15816534T 2014-12-12 2015-12-10 Tratamiento de metástasis cerebrales del cáncer de mama Active ES2784900T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462091200P 2014-12-12 2014-12-12
PCT/IB2015/059525 WO2016092508A1 (en) 2014-12-12 2015-12-10 Treatment of breast cancer brain metastases

Publications (1)

Publication Number Publication Date
ES2784900T3 true ES2784900T3 (es) 2020-10-01

Family

ID=55024190

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15816534T Active ES2784900T3 (es) 2014-12-12 2015-12-10 Tratamiento de metástasis cerebrales del cáncer de mama

Country Status (6)

Country Link
US (1) US10689459B2 (enExample)
EP (1) EP3229803B1 (enExample)
JP (1) JP6847835B2 (enExample)
CN (1) CN108367003B (enExample)
ES (1) ES2784900T3 (enExample)
WO (1) WO2016092508A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110115758B (zh) * 2018-02-05 2021-05-11 中山大学 Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
US20110033453A1 (en) * 2008-03-05 2011-02-10 Carlos Garcia-Echeverria Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
AU2013302702A1 (en) 2012-08-16 2015-02-19 Novartis Ag Combination of Pl3K inhibitor and c-Met inhibitor
WO2014177915A1 (en) * 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
JP6755235B2 (ja) 2014-07-16 2020-09-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 低悪性度漿液性癌におけるｈｅｒ３阻害

Also Published As

Publication number Publication date
US20190211110A1 (en) 2019-07-11
JP6847835B2 (ja) 2021-03-24
WO2016092508A9 (en) 2018-01-11
WO2016092508A1 (en) 2016-06-16
CN108367003B (zh) 2022-01-21
JP2018506511A (ja) 2018-03-08
EP3229803A1 (en) 2017-10-18
US10689459B2 (en) 2020-06-23
EP3229803B1 (en) 2020-01-29
CN108367003A (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
ES3055227T3 (en) Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
BR112021016149A2 (pt) Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
TW200940064A (en) Combination therapy with C-MET and EGFR antagonists
JP7783182B2 (ja) ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
CN106659772A (zh) 在疾病和紊乱的治疗中调节肾酶的组合物和方法
KR20230053686A (ko) Egfr 돌연변이를 갖는 비소세포 폐암의 치료
KR20240112963A (ko) 대장암을 치료하기 위한 아미반타맙의 용도
US20200347140A1 (en) Compositions and methods for treating cancer with anti-egfr antibodies
JP7094329B2 (ja) 低悪性度漿液性癌におけるｈｅｒ３阻害
US20230250195A1 (en) Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies
KR20220010731A (ko) 이중특이성 항-EGFR/c-Met 항체와 제3 세대 EGFR 티로신 키나제 억제제에 의한 병용 요법
US20250228858A1 (en) Anti-cancer combination therapy
US10689459B2 (en) Treatment of breast cancer brain metastases
JP2022554270A (ja) 抗ｐｄ－１抗体による癌を治療する方法
CN111886257A (zh) 用于疾病和病症治疗和预防的抗-肾酶抗体
WO2026038160A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
HK40116078A (zh) 用於减少使用egfr/met双特异性抗体治疗的患者的输注相关反应的方法
EA050376B1 (ru) ЛЕЧЕНИЕ ПАЦИЕНТОВ, ИМЕЮЩИХ МУТАЦИИ, ВЫЗЫВАЮЩИЕ ПРОПУСК ЭКЗОНА 14 В c-Met
HK40109502A (zh) 用於疾病和病症治疗和预防的抗-肾酶抗体
EA046908B1 (ru) Комбинированные терапии с использованием биспецифических антител к egfr/c-met и 3-го поколения ингибиторов тирозинкиназы egfr